Fitxers
Tipus de document
ArticleVersió
Versió publicadaData de publicació
Llicència de publicació
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/231818
Lessons From the ANTES B+ Study
Títol de la revista
Director/Tutor
Contribució addicional
ISSN de la revista
Títol del volum
Resum
About a year ago, Archivos de Bronconeumologia published the rationale, goals, design and methods of the ANTES B+ study [1], a pragmatic, prospective, randomized clinical trial whose primary objective was to investigate if treatment with inhaled triple therapy (LABA-LAMA-ICS) improved clinical control [2] during 12 months follow-up vs. the GOLD recommended dual therapy (LABA-LAMA) in a specific subgroup of GOLD B patients that we named B+ [3]. These B+ patients were characterized by having a CAT score >10 despite treatment with LABA-LAMA and having had a moderate exacerbation (treated with oral corticosteroids and/or antibiotics but not needing hospitalization) the year before and having more than 150 eosinophils/μL of circulating blood [1]. These inclusion criteria were based on previous observations that showed that: (1) patients who remain symptomatic (CAT >10) despite treatment with LABA-LAMA are at higher risk of worse health outcomes [3]; (2) GOLD B patients with 1 previous moderate exacerbation the year before had substantially higher hazard ratio of future exacerbation, all-cause hospitalization and respiratory hospitalization than those without them [4]; and (3) that higher level of circulating eosinophils identifies patients with a higher risk of future ECOPD, a better preventive response to inhaled corticosteroids (ICS), and reduced risk of ICS-related pneumonia [5]. Indeed, this hypothesis was proposed before the Global Initiative for Chronic Obstructive Lung Disease (GOLD) suggested in the 2026 GOLD recommendations to consider one moderate exacerbation enough to move the patient to the GOLD E group [6]. Finally, but importantly, this was going to be the first clinical trial with a composite outcome (clinical control) as the main endpoint. The concept of disease activity, disease stability and clinical control has also been highlighted in GOLD 2026 for the first time.
Recurs relacionat
Matèries
Matèries (anglès)
Citació
Citació
AGUSTÍ GARCÍA-NAVARRO, Àlvar, SOLER CATALUÑA, Juan José and ANTES program. Lessons From the ANTES B+ Study. Archivos de Bronconeumologia. 2026. Vol. 62, num. 7, pags. 503-504. ISSN 0300-2896. [consulted: 17 of October of 2026]. Available at: https://hdl.handle.net/2445/231818